Page 12 - TD-2-2
P. 12
Tumor Discovery Practice and consideration of master protocol design
(Cont’d...)
Primary endpoint
Sample size
Target
Drug(s) 7. Ganetespib 8. ABT-888 9. Neratinib 10. PLX3397 11. Pembrolizumab-4 cycle 12. Talazoparib+ irinotecan 13. Patritumab and trastuzumab 14. Pembrolizumab-8 cycle 15. SGN-LIV1A 16. Durvalumab+ olaparib 17. SD-101+ pembrolizumab 18. Tucatinib+ trastuzumab and pertuzumab 19. Cemiplimab 20. Cemiplimab+ REGN3767 21. Trilaciclib with or without trastuzumab+ pertuzumab 22. SYD985 ([vic-] trastuz
Design
Description
Registration number
Table 1. (Continued) Trial
Volume 2 Issue 2 (2023) 6 https://doi.org/10.36922/td.342
